Decision Resources Group has released the Biosimilar Advisory Service: Corporate Strategies report on partnership activity in the biosimilar space, which shows a 34% increase in 2013 compared with 2012. According to the report, this increase was driven by the need for companies to augment internal capabilities with market players in order to enter the biosimilar space. The high number of partnerships is attributed to the complexity of bringing a biosimilar from development to market.
According to Decision Resources Group, the market share of biosimilar sales is estimated to be more than $19.5 billion in 2022 in the U.S., Japan, Germany, France, the UK, Italy and Spain.
The report also highlighted that innovator companies must adopt strategies to minimize sales losses over the 2013 to 2022 forecast period, and biosimilar manufacturers are employing novel clinical development strategies such as three-arm Phase I trials, to help streamline later clinical development.
Additional report findings suggest that endorsement of early adopter physicians will be instrumental in differentiating and driving the uptake of a specific biosimilar over competitor biosimilars of the same reference molecule. Also, legislation on the automatic substitution of biosimilars is continuing to evolve, in some cases, allowing limited pharmacy-level substitution.
Decision Resources Group Analyst Anees Malik, said, "We continue to see aggressive partnership activity in the biosimilar space, particularly from emerging market developers, highlighting an awareness of the breadth of capabilities required to bring a biosimilar to the global market and an indication of the increasing number of market players making a bet on biosimilars."
"Both biosimilar developers and innovator companies have to determine the optimum strategies to pursue in an area which is highly dynamic and where the opinion of key stakeholders is still fluid," Malik added.